Empresas Premium
.jpg){kind=logo}
This article explores the consequences for companies manufacturing active pharmaceutical ingredients (APIs) which export and import to the European Union and whose plants are located in the United Kingdom or have a relationship with the country. It outlines and lists the different sectors affected by Brexit and the existing solutions for those countries not members of the European Union.
This article aims at providing a quick overview of some of the sectors affected by the UK’s leaving the European Union. There are numerous implications which will unfold with time, and this is why the author does not seek to cover the entire pharmaceutical sector affected but aims at providing a brief comment on the situation as it stands before those involved start laying down conditions and barriers where they previously did not exist, which will likely lead to further opinions.
